Dr. Pick works in the Oak Tree Clinic as well as for Internal Medicine in BC Women’s Hospital. She has extensive experience in HIV care and sits on the BC Centre for Excellence in HIV/AIDS Therapeutic Guideline Committee, as well as the Community Advisory Committee for Patient Safety. She has a special interest in women’s health.
Recently Dr. Pick, part of a team of three primary investigators, received a grant to lead a pan-Canadian study examining accelerated aging in women resulting from HIV infection or antiretroviral therapy (ART). More information can be found at – http://med.ubc.ca/ubc-to-lead-national-study-of-hivs-effects-on-women-and-their-children/
Dr. Pick has also received a catalyst grant from the Canadian Institutes of Health Research to explore telomere length and neurocognition in HIV+ women in the HAART era (Highly Active Anti-Retroviral Therapy).
- HIV and Hepatitis C
- Human papillomavirus
- Tuberculosis, HIV, and Menopause
- Neurocognition in the HIV aging population
Loufty M, Walmsley A, Klein M, Raboud J, Tseng A, Blitz S, Pick N, Conway B, Angel J, Rachlis A, Gough K, Cohen J, Haase D, Burdge D, Smaill F, Pokomandy A, Loemba H, Trottier S, La Porte C. Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy. Submitted to the British Journal of Clinical Pharmacology on 1st April 2012.
Klein M, Rollet K, Saeed S, Cox J, Potter M, Cohen J, Conway B, Cooper C, Côté P, Gill J, Haase D, Haider S, Hull M, Moodie E, Montaner J, Pick N, Rachlis A, Rouleau D, Sandre R, Tyndall M, Walmsley S. HIV and Hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. Canadian HIV-HCV Cohort Investigators. HIV Med. 2012 May 28. doi: 10.1111/j.1468-1293.2012.01028.x. [Epub ahead of print]
Hull MW, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB, the Canadian Co-infection Cohort Study Investigators. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/HCV co-infected patients. AIDS. 2012 Sep 10; 26(14):1789-94.
Côté HC, Soudeyns H, Thorne A, Alimenti A, Lamarre V, Maan EJ, Sattha B, Singer J, Lapointe N, Money DM, Forbes J; CIHR Emerging Team in HIV therapy, aging (CARMA), Wong J, Bitnun A, Samson L, Brophy J, Burdge D, Pick N, van Schalkwyk J, Montaner J, Harris M, Janssen P. Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia. PLoS One. 2012; 7(7):e39266. Epub 2012 Jul 16.
Renouf LS, Sheps S, Hubley A, Pick N, Johansen D, Tyndall MW. The Role of Diet in Predicting Iron Deficiency Anemia in HIV-Positive Women. Canadian Journal of Dietetic Practice and Research. 2012 Fall; 73(3): 128-33.
Wang X, Salters KA, Zhang W, McCandless L, Money D, Pick N, Montaner J, Hogg R, Kaida A. Women’s Health Care Utilization among Harder-to-Reach HIV-Infected Women ever on Antiretroviral Therapy in British Columbia. AIDS Research and Treatment, vol. 2012, Article ID 560361, 9 pages, 2012. doi:10.1155/2012/560361.
Klein MB, Rollet KC, Hull M, Cooper C, Walmsley S, Conway B, Pick N, and the Canadian Co-infection Cohort Study (CTN222) Investigators. Who needs direct acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV co-infected persons. International Medical Press. doi: 10.3851/IMP2484. 2012.
Miller C, McMullin B, Ghaffari A, Stenzler A, Pick N, Roscoe D, Ghahary A, Road J, Av-Gay Y. Gaseous nitric oxide bactericidal activity retained during intermittent high-dose short duration exposure. Nitric Oxide. 2009 Feb;20(1):16-23.
Cowley S, Ko M, Pick N, Chow R, Downing K, Gordhan B, Betts J, Smith D, Mizrahi V, Stokes R, Av-Gay Y. The mycobacterium tuberculosis Protein Serine/Threonin kinase PknG mediates cellular Glutamate/Glutamine Levels and is required for Survival in vivo. Mol Microbiology. 2004 Jun;52(6):1691-702.